Technologies

The technology, developed by CNR-ICB, is based on an innovative bioprocess called "Caphnophilic (CO2-requiring) Lactic Fermentation (CLF)”, developed in the hyperthermophilic bacterium Thermotoga neapolitana (EP patent: EP2948556B1), which allows the production of "green" hydrogen and capture and valorization of CO2 in L -lactic acid (98% e.e.).

The development of functional foods is often limited by industrial manufacturing processes, for example, for the production of baked foods, the use of high cooking temperatures causes denaturation of proteins, destruction of vitamins, alteration of fatty acids, etc. The protection of these components is essential in the production of gluten-free foods as they are generally poor in proteins and vitamins.

The prototype uses soil moisture sensors which, through a measurement of dielectric permittivity, estimate the soil moisture based on which irrigation is started through relay-controlled solenoid valve. The system was developed using Open Source technologies. Specifically, for the hardware components, a small sized board computer Raspberry PI 3B + was used together with a 4G LTE Wi-Fi router and a Modbus rs485 / USB converter.

Our team can develop low-cost ultra-flexible sensors integrated on plastic substrate for volatile organic compounds (VOCs) and gas detection. These devices combine scalable fabrication technologies, implementing active materials such as nanostructured metal oxides or stack of nanostructures decorated with metal nanoparticles, thus enabling a high sensitivity (in the range of hundreds of ppb). These devices can be applied to numerous industrial and commercial sectors and they can be embedded in systems that are more sophisticated.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.